Insider Selling: Omeros (NASDAQ:OMER) Director Sells 15,000 Shares

Omeros Corporation (NASDAQ:OMER) Director Thomas Cable sold 15,000 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director owned 35,067 shares in the company, valued at $646,986.15. This represents a 29.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Omeros Price Performance

Shares of OMER traded up $0.64 during trading hours on Friday, hitting $19.27. The stock had a trading volume of 2,582,326 shares, compared to its average volume of 1,721,300. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 15.05 and a beta of 2.54. The company’s fifty day moving average is $11.52 and its two-hundred day moving average is $11.71. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.58.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. Equities analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on OMER shares. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. State of Wyoming acquired a new stake in shares of Omeros during the 4th quarter worth approximately $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros in the second quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros in the fourth quarter valued at approximately $33,000. Assetmark Inc. acquired a new stake in Omeros during the 1st quarter worth $38,000. Finally, Tower Research Capital LLC TRC grew its holdings in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.